First Republic Investment Management, Inc. Crinetics Pharmaceuticals, Inc. Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	SELL	$15.73 - $23.6 $6,402 - $9,605	-407 Reduced 2.06%	19,354 $348,000
Q1 2023 May 11, 2023	BUY	$15.31 - $21.1 $8,343 - $11,499	545 Added 2.84%	19,761 $317,000
Q4 2022 Feb 13, 2023	BUY	$15.49 - $19.05 $297,655 - $366,064	19,216 New	19,216 $351,000

Others Institutions Holding CRNX

# of Institutions

241

Shares Held

79.6M

Call Options Held

23.3K

Put Options Held

44.3K

Vanguard Group Inc Valley Forge, PA

6.29M
Shares

$344 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.23M
Shares

$341 Million
0.01% of portfolio
Driehaus Capital Management LLC Chicago, IL

5.89M
Shares

$322 Million
2.95% of portfolio
Price T Rowe Associates Inc Baltimore, MD

4.94M
Shares

$271 Million
0.03% of portfolio
Wellington Management Group LLP Boston, MA

4.46M
Shares

$244 Million
0.04% of portfolio

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.94B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account